US 7,320,790 B2 | ||
Humanized antibodies | ||
Paul Robert Hinton, Sunnyvale, Calif. (US); and Maximiliano J. Vasquez, Palo Alto, Calif. (US) | ||
Assigned to Eli Lilly and Company, Indianapolis, Ind. (US) | ||
Appl. No. 10/497,475 PCT Filed Apr. 26, 2002, PCT No. PCT/US02/11854 § 371(c)(1), (2), (4) Date Jan. 10, 2005, PCT Pub. No. WO02/088307, PCT Pub. Date Nov. 07, 2002. |
||
Claims priority of provisional application 60/287653, filed on Apr. 30, 2001. | ||
Prior Publication US 2005/0142131 A1, Jun. 30, 2005 | ||
Int. Cl. A61K 39/395 (2006.01); C12P 21/08 (2006.01); C07K 16/18 (2006.01); C07H 21/04 (2006.01); C12N 5/16 (2006.01) |
U.S. Cl. 424—133.1 [530/387.3; 530/387.9; 536/23.53; 435/328; 435/331; 424/139.1; 424/141.1] | 17 Claims |
1. An antibody comprising a light chain variable region comprising SEQ ID NO:9 and a heavy chain variable region comprising SEQ ID NO:10. |